View in EDS HTML Full Text PDF Full Text

No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC.

Saved in:
Bibliographic Details
Title: No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC.
Authors: Copil, Francisca‐Dora1 (AUTHOR), Campani, Claudia2 (AUTHOR), Lequoy, Marie3 (AUTHOR), Sultanik, Philippe1 (AUTHOR), Blaise, Lorraine4 (AUTHOR), Wagner, Mathilde5 (AUTHOR), Ganne‐Carrié, Nathalie2,4 (AUTHOR), Ozenne, Violaine3 (AUTHOR), Thabut, Dominique1,6 (AUTHOR), Nault, Jean‐Charles2,4 (AUTHOR), Ratziu, Vlad1,6 (AUTHOR), Allaire, Manon1,2,7 (AUTHOR) manon.allaire@aphp.fr
Source: Liver International. Apr2024, Vol. 44 Issue 4, p931-943. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14783223
DOI:10.1111/liv.15833